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The nicotinamide adenine dinucleotide phosphate (NADPH) oxidase expressed in phago-
cytes is a multi-subunit enzyme complex that generates superoxide (O .2 −). This radical is
an important precursor of hydrogen peroxide (H2O2) and other reactive oxygen species
needed for microbicidal activity during innate immune responses. Inherited defects in
NADPH oxidase give rise to chronic granulomatous disease (CGD), a primary immunodefi-
ciency characterized by recurrent infections and granulomatous inflammation. Interestingly,
CGD, CGD carrier status, and oxidase gene polymorphisms have all been associated with
autoinflammatory and autoimmune disorders, suggesting a potential role for NADPH oxi-
dase in regulating adaptive immune responses. Here, NADPH oxidase function in antigen
processing and presentation is reviewed. NADPH oxidase influences dendritic cell (DC)
crosspresentation by major histocompatibility complex class I molecules through regula-
tion of the phagosomal microenvironment, while in B lymphocytes, NADPH oxidase alters
epitope selection by major histocompatibility complex class II molecules.
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NADPH OXIDASE
The phagocyte nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase complex catalyzes electron transfer from
NADPH to molecular oxygen and thus generates superoxide
(O2.−), the precursor of H2O2 and other reactive oxygen species
(ROS) necessary for the microbicidal activity of neutrophils and
other phagocytes during innate immune responses. The active
phagocyte oxidase (phox) complex consists of five subunits and
the small GTPase Rac. The catalytic core of the complex, which
displays little to no activity in resting phagocytic cells, is comprised
of two transmembrane subunits, gp91phox (often referred to as
NOX2) and p22phox. These proteins form a heterodimer known
as flavocytochrome b558 in vesicular and plasma membranes of
neutrophils and other leukocytes. In response to stimuli, the regu-
latory subunits p47phox, p67phox, and p40phox, which together exist
as a complex in the cytosol, translocate along with Rac-GTP to
the membrane-bound catalytic core to form the active enzyme
complex (Figure 1) (1–3).
CHRONIC GRANULOMATOUS DISEASE
Inherited mutations in the subunits of NADPH oxidase result in
chronic granulomatous disease (CGD), a primary immunodefi-
ciency disorder affecting at least 1 in 250,000 individuals in the US
(4). X-linked CGD, the most common genetic subgroup, is caused
by mutations in gp91phox. X-linked CGD accounts for approx-
imately 70% of CGD cases and affects mostly males, although
female carriers with skewed X-chromosome inactivation can also
display a CGD phenotype (4–7). Mutations in p22phox, p47phox,
and p67phox can also give rise to CGD through autosomal recessive
inheritance. Patients with autosomal recessive forms of CGD are
often diagnosed later in life, exhibit a milder clinical phenotype,
and live longer than patients with X-linked CGD (4, 7). Isolated
cases of children with a CGD phenotype having mutations in Rac2
(8) and p40phox (9) have also been described.
Phagocytes lacking functional NADPH oxidase are unable to
produce ROS necessary to kill certain pathogenic bacteria and
fungi. Thus, patients with CGD experience recurrent infections,
most often with catalase positive organisms. Patients are also
prone to develop severe granulomas resulting in obstructive lesions
in the esophagus, stomach, and urinary tract (4, 7, 10, 11). In
a cohort of 368 CGD patients from the US, pneumonia was
the most common form of infection (79% of patients with at
least one episode), and 41% of these infections were caused by
Aspergillus spp. Abscesses were also common (68% of patients
with at least one episode). Additionally, suppurative adenitis,
osteomyelitis, septicemia, cellulitis, and meningitis were reported
(4). Similar data were described in a European cohort of 429 CGD
patients (7). In both cohorts, the most common causes of death
were infections involving Aspergillus spp. and Burkholderia cepacia
(4, 7).
CGD AND AUTOIMMUNITY
Remarkably, CGD is also associated with a number of autoin-
flammatory and autoimmune disorders. Several patients with
systemic lupus erythematosus (SLE) and discoid lupus erythe-
matosus (DLE) have been described (4, 7, 12, 13). In addition,
lupus has also been widely reported in female carriers of X-CGD
(4, 7, 12–15). A number of other studies have pointed to an
association of CGD with autoimmune arthritis (7, 15, 16). CGD
patients with colitis-like symptoms (4, 9) similar to inflammatory
bowel disease, myasthenia gravis (4), immune thrombocytopenia
(4, 7), sarcoidosis (17), pericardial effusion, IgA nephropathy, and
aphthous stomatitis (15) have also been described.
In addition to this well-established connection between CGD
and autoimmunity, genes encoding oxidase subunits have been
associated with autoinflammatory and autoimmune disorders in
genome-wide association studies (GWAS). A variation in NCF2,
the gene encoding p67phox, has been identified as an important
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FIGURE 1 | NADPH oxidase structure. NADPH oxidase is a multi-subunit
enzyme complex present in the vesicular and plasma membranes of
leukocytes. Two transmembrane subunits, gp91phox and p22phox, make up
flavocytochrome b558, the catalytic core of the complex. This heterodimer
catalyzes the transfer of electrons from cytosolic NADPH to molecular
oxygen, thus generating superoxide. Flavocytochrome b558 is regulated by
association with the subunits p47phox, p67phox, and p40phox along with the
small GTPase Rac. These regulatory subunits are present in the cytosol of
resting cells and translocate to the catalytic core following stimulation.
risk factor for SLE (18). NCF4, encoding p40phox, has been associ-
ated with rheumatoid arthritis (19) and Crohn’s disease (20, 21).
In the absence of NADPH oxidase activity, murine dendritic cells
(DC) produce elevated levels of inflammatory cytokines that alter
helper T cell differentiation and promote development of collagen-
induced arthritis (22, 23). These findings suggest NADPH oxidase
may be playing an important role not only in innate immune
responses, but also in adaptive immune responses.
NADPH OXIDASE AND CROSSPRESENTATION
Several studies have looked into the relationship between NADPH
oxidase activity and antigen crosspresentation. DC, and to a lesser
extent, macrophages, are capable of crosspresentation, a process by
which peptides derived from exogenous antigens are loaded onto
and presented by major histocompatibility complex class I (MHC-
I) molecules. During crosspresentation, exogenous antigens, either
particulate or soluble, are phagocytosed or endocytosed. These
antigens are proteolytically processed to short peptides, 8–10
amino acids long, and subsequently loaded onto MHC-I. Crossp-
resentation has been implicated in infection responses where unin-
fected DC play a critical role in CD8+ T cell activation (24–26).
Crosspresentation of self and environmental antigens may also
play a role in the maintenance of central and peripheral tolerance,
implicating crosspresentation in the development of autoimmune
disorders and as a potential target for immunotherapy (27–30).
The pathways by which exogenous antigens encounter MHC-I
are incompletely understood. Some studies have shown crosspre-
sentation is dependent on proteasome activity, suggesting exoge-
nous antigens are transported into the cytosol for processing
(31, 32). In DC, studies have shown phagosomes fuse with the
endoplasmic reticulum (ER), and antigenic peptides processed
in the cytosol are transported by TAP back into the phago-
some lumen before being loaded onto MHC-I (33). Other studies
indicate exogenous antigens are processed within phagosomes
and endosomes prior to intersecting MHC-I, independent of the
FIGURE 2 | Potential roles of NADPH oxidase in antigen presentation.
MHC-I and MHC-II are both present in phagosomes and endosomes of
antigen presenting cells. For simplicity, MHC-I has been shown in a
phagosome, while MHC-II has been shown in an endosome. During
crosspresentation, exogenous antigens can be processed within these
compartments by proteases, prior to loading onto MHC-I. NADPH oxidase
has been shown to regulate antigen processing and MHC-I
crosspresentation in DC; however, whether NADPH oxidase regulates this
process by modulating the phagosomal pH or redox microenvironment is
currently debated. During classical MHC-II presentation, exogenous
antigens are processed within vesicular compartments by proteases and
GILT. Following the removal of CLIP by HLA-DM, processed peptides are
loaded onto MHC-II. NADPH oxidase can also regulate MHC-II presentation
in B cells by altering the peptide repertoire displayed by MHC-II, possibly in
favor of self antigens. However, the mechanism underlying this
phenomenon is still unclear. Whether or not NADPH oxidase, MHC-I and -II,
and the antigen processing machinery co-localize within the same vesicular
compartment also remains to be elucidated.
proteasome and TAP (Figure 2) (34, 35). In DC, Amigorena
and colleagues identified a central role for NADPH oxidase in
modulating the efficiency of antigen degradation and MHC-I
crosspresentation to CD8+ T cells.
To investigate in vivo oxidase function in crosspresentation,
wild type and gp91phox-deficient mice were immunized with oval-
bumin coupled to an antibody specific for the receptor DEC205,
targeting this antigen-antibody complex to murine DC. CD8+ T
cells that recognize epitopes from ovalbumin in the context of
MHC-I were adoptively transferred into recipient wild type or
oxidase-deficient mice, followed by an analysis of T cell activa-
tion (36). Ovalbumin-specific T cell activation was significantly
less efficient in gp91phox-deficient mice compared to wild type
mice. Results in vitro also showed gp91phox-deficient DC did not
efficiently crosspresent ovalbumin to antigen-specific CD8+ T
cells compared to wild type DC. However, presentation of the
pre-processed ovalbumin SIINFEKL peptide was similar in both
DC populations. Together, these data suggest gp91phox is impor-
tant for antigen processing and crosspresentation in murine DC
(36).
Similarly, in vitro human CD8+ T cell recognition of an HLA-
A2-restricted extended MelanA/MART-1 peptide was reduced in
DC from CGD patients and in DC treated with an oxidase inhibitor
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compared to wild type DC, whereas presentation of a shorter form
of this peptide was not affected (37). Chemical inhibition of the
oxidase did not alter DC phagocytosis. Given that crosspresenta-
tion of the long, but not short, MelanA/MART-1 peptide requires
processing by DC, these results indicate an important role for
NADPH oxidase in antigen processing and crosspresentation by
human DC (37).
Amigorena and colleagues found this effect of NADPH oxidase
on crosspresentation occurs in murine CD8+ but not CD8− DC.
Rac2, the small GTPase which facilitates oxidase subunit assem-
bly on phagosomal membranes, was also required for efficient
crosspresentation (38).
Precisely how loss of oxidase function disrupts MHC-I crossp-
resentation remains controversial. Amigorena and colleagues have
proposed in DC that NADPH oxidase promotes an alkaliniza-
tion of the phagosome lumen thus limiting antigen proteolysis
and preserving epitopes for crosspresentation by MHC-I (36–39).
FACS-based studies using pH sensitive fluorophores coupled to
latex beads revealed pH values of 7.5 or higher after phagocy-
tosis in phagosomes of DC with functional oxidase, while rapid
acidification of phagosomes was observed in DC from gp91phox-
deficient mice (36). Loss of ovalbumin on coated beads after
phagocytosis suggested enhanced degradation of this antigen in
gp91phox-deficient cells compared with wild type DC, consistent
with a role for the oxidase in limiting antigen processing for
crosspresentation (36).
Yates and colleagues also found in the absence of functional
NADPH oxidase, the rate of phagosomal proteolysis in DC was sig-
nificantly increased compared to cells with normal oxidase activity
(40). However, results of excitation ratio fluorometry and real-
time fluorometric confocal microscopy experiments suggested
NADPH oxidase activity does not prevent acidification of DC
phagosomes (40).
To determine an alternative mechanism by which NADPH oxi-
dase activity limits antigen proteolysis, the effect of oxidase activ-
ity on different classes of proteases was examined. Phagosomal
hydrolysis of fluorogenic substrates for cysteine cathepsins B/S/L
and aspartic cathepsins D/E was monitored in oxidase-proficient
and -deficient DC in real time. NADPH oxidase ROS produc-
tion inhibited phagosomal cysteine, but not aspartic, cathepsin
activity. This inhibition also occurred in the presence of H2O2
in a reconstituted system of lysosomal extracts and could be
reversed upon addition of reduced glutathione, suggesting oxi-
dase activity may limit antigen proteolysis through redox mod-
ulation of cysteine cathepsin activity. Using an assay with bead
coupled cysteine-linked fluorochromes, disulfide bond reduc-
ing capacity was also found to be markedly inhibited within
phagosomes of wild type DC compared to gp91phox-deficient
DC, suggesting NADPH oxidase activity may also be important
for regulating disulfide bond reduction in antigen processing
events (40).
Discrepancies regarding the effect of NADPH oxidase activity
on phagosomal pH in DC remain. However, all studies highlight a
role for NADPH oxidase in limiting antigen proteolysis in phago-
somes (36, 40). Whether the reduced antigen crosspresentation
by DC outlined in these reports perturbs the development of self
tolerance in CGD patients remains unclear.
NADPH OXIDASE AND MHC-II ANTIGEN PRESENTATION
A new genetic subgroup of CGD was recently defined upon
identification of a patient with autosomal recessive mutations
in both copies of NCF4, the gene encoding p40phox (9). Famil-
ial studies to track p40phox mutations in this patient revealed
the paternal allele encodes a truncated protein due to the pres-
ence of a premature stop codon. The maternal allele contains an
R105Q missense mutation in the phospholipid binding PX (phox
homology) domain. In neutrophils, this mutation results in a loss
of p40phox phosphatidylinositol (3,4,5)-triphosphate binding fol-
lowed by premature dissociation from the neutrophil phagosome
and ultimately impaired production of intracellular ROS by the
oxidase complex (9).
This patient did not initially present with recurrent patho-
genic infections characteristic of CGD, but rather with severe
granulomatous colitis (9). NCF4 has been associated with ileal
Crohn’s disease (20, 21) as well as rheumatoid arthritis (19) in
GWAS. These linkages to autoinflammatory and autoimmune dis-
orders suggest a potential role for p40phox in regulating adaptive
immune responses. Supporting this hypothesis, human B lym-
phocytes lacking functional p40phox exhibit altered antigen pre-
sentation by major histocompatibility complex class II (MHC-II)
molecules (41).
MHC-II molecules are heterodimeric transmembrane proteins
composed of α and β subunits. Within professional antigen pre-
senting cells, these αβ heterodimers are loaded with peptides
derived from processed protein antigens prior to cell surface pre-
sentation to CD4+ T cells. MHC-II assemble in the ER where
they bind invariant chain (Ii) (42). Ii stabilizes the MHC-II het-
erodimer and directs the trafficking of MHC-II through the Golgi
and into the endosomal network (43). Within this network, Ii is
systematically cleaved by acid proteases leaving class II-associated
invariant chain peptide (CLIP) bound to the MHC-II binding
groove (44–46). In endosomes, HLA-DM, a non-classical MHC-II
protein, catalyzes the removal of CLIP, and further edits peptides
that bind MHC-II to favor the presentation of stable antigenic
epitopes (Figure 2) (47, 48).
Antigenic peptides capable of binding MHC-II are gener-
ated within the endosomal network by proteases active at acidic
pH, including cathepsins and asparaginyl endopeptidase (AEP)
(49). Antigen proteolysis can be influenced by gamma-interferon-
induced lysosomal thiol reductase (GILT). This enzyme reduces
antigen disulfides to favor protein unfolding at acidic pH (50, 51).
Whether or not NADPH oxidase co-localizes with MHC-II, GILT,
and acidic proteases in endosomes remains unclear (Figure 2).
Interestingly, evidence also suggests a role for ROS in regulat-
ing antigen presentation by MHC-II. In phagocytes, nitric oxide
production is required for processing bacterial polysaccharides
into fragments capable of binding MHC-II for presentation to T
cells (52). Conflicting reports with B lymphocytes also suggest
roles for superoxide and NADPH oxidase in MHC-II presen-
tation, yet these early studies employed samples from reported
CGD patients without genetic analysis to confirm defective oxi-
dase subunits (53, 54). Although B lymphocytes express functional
NADPH oxidase subunits (55), the precise function of this enzyme
complex in these cells remains unclear. Analysis of CGD patient
B cells (56, 57) revealed alterations in circulating memory B cells;
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however, inactivation of the oxidase also impacts T lymphocyte
development and function (58–60).
To examine the role of the oxidase in cytoplasmic antigen pre-
sentation by MHC-II, p40phox expression in a human B cell line
was disrupted using lentiviral-driven shRNA (41). In B lympho-
cytes, p40phox deficiency altered the profile of antigenic epitopes
displayed by MHC-II, with a shift toward preferential presenta-
tion of self membrane-associated antigens. Studies using a panel
of antigen-specific T cells revealed MHC-II presentation of epi-
topes from cytoplasmic and exogenous antigens was reduced with
knockdown of p40phox in B cells. Yet, MHC-II presentation of epi-
topes from membrane antigens was enhanced for B cells deficient
in p40phox when compared to parental or control cells with nor-
mal levels of this subunit. MHC-II presentation of synthetic short
peptides by p40phox-deficient B cells was comparable to control
cells, revealing that loss of this subunit did not influence pep-
tide binding to surface MHC-II or T cell recognition of these
complexes. Consistent with these results, surface levels of HLA-
DR in parental and control shRNA-treated cells were equivalent
(41). These results suggest that diminished p40phox expression may
modulate the balance of foreign versus self antigen presented in
the context of MHC-II in human B cells.
To determine whether spontaneously arising mutations in
human p40phox influence MHC-II presentation, B lymphoblas-
toid cells were generated from the CGD patient with mutations in
NCF4 (9) and transduced to express the MHC-II allele DRβ1*0401
(61). These patient-derived cells were also transduced to express
functional wild type p40phox or the mutant R105Q allele (41). In
agreement with previous results, reduced CD4+ T cell responses
were detected in response to exogenous antigens in patient B cells
with mutated p40phox compared to patient cells reconstituted with
wild type p40phox. MHC-II presentation of epitopes from endoge-
nous, self membrane antigens was similar regardless of the form
of p40phox expressed by these B cells. T cell responses to synthetic
peptides presented in the context of MHC-II on patient-derived
B cells were comparable for cells expressing mutant or wild type
forms of p40phox (41).
Notably, presentation of exogenous tetanus toxoid was also
reduced in B cells from CGD patients with mutations in gp91phox
as well as B cells from the patient with mutations in p40phox. No
differences were observed in the expression levels of key compo-
nents of the MHC-II pathway including HLA-DR, -DM, or -DO
in B cells from the patient with NCF4 mutations. While reduced
presentation of exogenous antigens was consistently observed with
reduced oxidase p40phox, the ability of these B cells to endocytose
antigen was similar to cells from healthy individuals. Flow cyto-
metric analysis revealed patient-derived B cells deficient in p40phox
spontaneously produced less intracellular superoxide compared
to these CGD cells with restored wild type p40phox expression.
Yet as observed in patient neutrophils (9), extracellular ROS
production in response to PMA was similar for the patient and
wild type p40phox-reconstituted B cells (41). Taken together, these
data suggest the altered profile of epitopes selected for presen-
tation in p40phox-deficient B cells may be linked to diminished
intracellular superoxide production.
While p40phox is known to regulate oxidase activation in
response to specific stimuli in neutrophils, this marks the first
demonstration of a role for p40phox in antigen presentation and B
cell functions. These results suggest functional p40phox expression
can influence the peptide repertoire presented by MHC-II on B
cells and the subsequent activation of CD4+ T cells. Thus, p40phox
deficiency may contribute to autoimmune and autoinflamma-
tory disease predisposition in patients with CGD or oxidase gene
polymorphisms.
CONCLUSION
Inherited defects in NADPH oxidase give rise to CGD, a pri-
mary immunodeficiency that has been linked with a number
of autoinflammatory and autoimmune disorders. Genes encod-
ing the subunits of NADPH oxidase have also been associated
with these disorders in GWAS. Together, these observations sug-
gest a potential role for NADPH oxidase in regulating adaptive
immune responses. Currently, studies have shown NADPH oxi-
dase activity limits antigen proteolysis in DC phagosomes to pro-
mote MHC-I crosspresentation; however, the mechanism under-
lying this effect remains unclear. Some studies suggest NADPH
oxidase activity limits antigen proteolysis by preventing phago-
some acidification, while others suggest it alters the local redox
microenvironment within the phagosome. Studies from our lab-
oratory have shown NADPH oxidase also modulates MHC-II
presentation in B cells and that defects in oxidase activity may
alter the peptide repertoire displayed by MHC-II. This phenom-
enon could contribute to the development of autoimmunity in
patients with CGD or polymorphisms in oxidase genes. Future
studies are needed to further establish this link as well as to eluci-
date the mechanism by which NADPH oxidase regulates antigen
presentation.
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